CTI BioPharma blood cancer drug meets main goal in trial

[March 09, 2015] (Reuters) - CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study.

Data from the study showed that the drug, pacritinib, was significantly better than the "best available therapy" as prescribed by the patients' physician to treat myelofibrosis.

Myelofibrosis is a form of blood cancer that makes the bone marrow produce too much of any type of blood cells.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.